SOMATOSTATIN ANALOGUES FOR THE TREATMENT OF NEUROENDOCRINE TUMOURS. DOSAGE FORMS AND ROUTES OF ADMINISTRATION (REVIEW)

  • Zoya Shprakh N.N. Blokhin NMRCO

Abstract

This review summarises information on drug products - analogues of somatostatin, which are included into the algorithm of neuroendocrine tumours treatment. The need for long-term use of somatostatin analogues requires the development of dosage forms that ensure the controlled release of the active substance over a considerable time. Usability of drugs for patients and medical personnel is also of high importance. This review attempts to analyze modern dosage forms of somatostatin analogues with improved pharmacokinetic and therapeutic characteristics present on the pharmaceutical market.

Keywords: Neuroendocrine tumours, Somatostatin analogues, Dosage form of prolonged-release, Oral administration

References

1. Fraenkel M, Fagiano A, Valk GD. Epidemiology of Neuroendocrine Tumors. Front Horm Res 2015;44:1-23.
2. Jimenez-Fonseca P, Carmona-Bayonas A, Martín-Pérez E, Crespo G, Serrano R, Llanos M et al. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev 2015;3:381-400.
3. Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-Guibert J, Pyronnet St et al. Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends Endocrinol Metab 2014;3:115-27.
4. Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016;1:163-77.
5. Mazziotti G, Mosca A, Frara S, Vitale G, Giustina A. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opin Pharmacother 2017;16:1679-89.
6. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008;3: 701-20.
7. Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009;12:2989-99.
8. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly - 2011 update executive summary. Endocr Pract 2011;17 Suppl 4:1-44.
9. Patel D, Chan D, Cenic G, Pavlakis N, Proce TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumorsd. Expert Rev Endocrinol Metab 2016;4:311-27.
10. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013;4:557 - 77.
11. Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol 2012;4:282-93.
12. Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther 2015;152:98-110.
13. Bousquet C, Lasfargues C, Chalabi M, Billah SM, Susini C, Vezzosi D et al. Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab 2012;3:727-37.
14. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9.
15. Massironi S, Zilli A, Conte D. Somatostatin analogs for gastric carcinoids: For many, but not all. World J Gastroenterol 2015;22:6785-93.
16. Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res 2012;5:161-8.
17. Crabtree JS. Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. Front Endocrinol 2017;8:341.
18. Ruscica M, Arvigo M, Steffani L, Ferone D, Magni P. Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression. Curr Mol Med 2013;4: 555-71.
19. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;2:600-6.
20. Tiberg F, Johnsson M, Jankunec M, Barauskas J. Phase behavior, functions, and medical applications of soy phosphatidylcholine and diglyceride lipid compositions. Chem Lett 2012;10:1090-2.
21. Tiberg F, Johnsson M. Drug delivery applications of non-lamellar liquid crystalline phases and nanoparticles. J Drug Del Sci Tech 2011;1:101-9.
22. Tiberg F, Roberts J, Cervin C, Johnsson M, Sarp S, Tripanti AP et al. Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. Br J Clin Pharmacol 2015;3:460-72.
23. Tekade RK, editor. Biomaterials and bionanotechnology (Advances in pharmaceutical product. Development and research series) 1st ed. Ahmedabad: Academic Press (Elsevier);2019.
24. Chieffo C, Cook D, Xiang Q, Frohman LA. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab 2013;10:4047-54.
25. Gadelha MR, Chieffo C, Bai SA; Hu X, Frohman LA. A subcutaneous octreotide hydrogel implant for the treatment of acromegaly. Endocr Pract 2012;6:870-81.
26. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 2005;28(11 Suppl International):36-42.
27. Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G, Arosio M et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest. 2009;3:297-303.
28. Siepmann J, Faisant N, Akiki J, Richard J, Benoit JP. Effect of the size of biodegradable microparticles on drug release: experiment and theory. J Control. Release 2004;1:123-34.
29. Estey T, Kang J, Schwendeman SP, Carpenter JF. BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems. J Pharm Sci 2006;7: 1626-39.
30. Lewis AL, Illum L. Formulation strategies for sustained release of proteins. Ther Deliv 2010;3:457-79.
31. Gobeaux F, Fay N, Tarabout C, Mériadec C, Meneau F, Ligeti M et al. Structural role of counterions adsorbed on self-assembled peptide nanotubes. J Am Chem Soc 2012;1:723-33.
32. Gobeaux F, Fay N, Tarabout C, Meneau F, Mériadec C, Delvaux C et al. Experimental observation of double-walled peptide nanotubes and monodispersity modeling of the number of walls. Langmuir 2013;8:2739-45.
33. Pandit A, Fay N, Bordes L, Valéry C, Cherif-Cheikh R, Robert B et al. Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues. J Pept Sci 2008;1:66-75.
34. Pouget E, Dujardin E, Cavalier A, Moreac A, Valéry C, Marchi-Artzner V et al. Hierarchical architectures by synergy between dynamical template self-assembly and biomineralization. Nat Mater 2007;6:434-39.
35. Pouget E, Fay N, Dujardin E, Jamin N, Berthault P, Perrin L et al. Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates. J Am Chem Soc 2010;12:4230-41.
36. Valery C, Artzner F, Robert B, Gulick T, Keller G, Grabielle-Madelmont C et al. Self-association process of a peptide in solution: from beta-sheet filaments to large embedded nanotubes. Biophys J 2004;4:2484-501.
37. Valery C, Pouget E, Pandit A, Verbavatz JM, Bordes L, Boisdé I et al. Molecular origin of the self-assembly of lanreotide into nanotubes: a mutational approach. Biophys J 2008;5:1782-95.
38. Gobeaux F, Fay N, Tarabout C, Mériadec C, Meneau F, Ligeti M et al. Structural role of counterions adsorbed on self-assembled peptide nanotubes. J Am Chem Soc 2012;1:723-33.
39. Troconiz IF, Cendros JM, Peraire C, Ramis J, Garrido MJ, Boscani PF et al. Population pharmacokinetic analysis of Lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet 2009;1:51-62.
40. Buil-Bruna N, Garrido M, Dehez M, Manon A, Nguyen THQ,Gomez-Panzani EL et al. Population pharmacokinetic analysis of Lanreotide Autogel (®)/Depot in the treatment of neuroendocrine tumors: pooled analysis of four clinical trials. Clin Pharmacokinet 2016;4:461-73.
41. Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl) 2012;5:103-9.
42. Witek P, Mucha S, Ruchata M. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly. Endokrynol Pol 2016;6:572-9.
43. Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J et al. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. J Gastrointest Cancer 2016;4:366-74.
44. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;12:1733-42.
45. Oberg K, Kvols LK, Caplin M, Delle Fave G, de Herder W, Rindi G et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;6:966-73.
46. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;5:707-16.
47. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;1-2:69-74.
48. Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther 2012;6:71-9.
49. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010;6:2781-9.
50. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med 2010; 19:1846-8.
51. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009;1:115-22.
52. Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther 2016;10:227-39.
53. Kvols LK, Oberg KE, O’Dorisio TM, Mohideen P, De Herder WW, Arnold R et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer 2012;5:657-66.
54. Norman P. Vapreotide (Debipharm). I Drugs 2000;11:1358-72.
55. Dasgupta P, Mukherjee R. Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro Br J Pharmacol 2000;1: 101-9.
56. Vapreotide (BMY 41606, RC 160, Sanvar®). Drugs in R&D 2003;4(5):326-30.
57. Shaji J, Patole V. Protein and Peptide Drug Delivery: Oral Approaches. Indian J Pharm Sci 2008;3:269-77.
58. Bak A, Leung D, Barrett SE, Forster S, Minnihan EC, Leithead AW et al. Physicochemical and Formulation Developability Assessment for Therapeutic Peptide Delivery - A Primer. AAPS J 2015;1:144-55.
59. Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012:2012:967347.
60. Dorkoosh FA, Verhoef JC, Verheijden JH, Rafiee-Tehrani M, Borchard G, Junginger HE Peroral absorption of octreotide in pigs formulated in delivery systems on the basis of superporous hydrogel polymers. Pharm Res 2002;10:1532-6.
61. Thanou M,Verhoef JC, Marbach P, Junginger HE. Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci 2000;7:951-7.
62. Thanou M, Verhoef JC, Verheijden JH, Junginger HE. Intestinal absorption of octreotide using trimethyl chitosan chloride: studies in pigs. Pharm Res 2001;6:823-8.
63. McCartney F, Gleeson JP, David J. Brayden DJ. Safety concerns over the use of intestinal permeation enhancers: A mini-review Tissue Barriers 2016;2:e1176822.
64. Tuvia S, Salama P, Weinstein I, Marom K, Neumark E, Arama ML et al. Octreolin a safe oral alternative for parenteral octreotide treatment. Growth Horm IGF Res 2010;20 Suppl 1:835-6.
65. Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012;7:2362-9.
66. Melmed S, Popovic V, Bidlingmaier M, Mercado M, Van Der Lely AJ, Biermasz N et al. Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. J Clin Endocrinol Metab 2015;4:1699-708.
67. Maggio ET, Grasso P. Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. Regul Pept 2011;2-3:233-8.
68. Osipov VN, Sushinina LP, Ustinkina SV, Smirnova LI, Shprakh ZS. Cyphetrylin cytotoxic analogues (report I). Russ J Biother 2016;4:85-8.
69. Borisova LM, Kiseleva MP, Osipov VN, Sushinina LP, Ustinkina SV, Smirnova LI, Shprakh ZS. Cyphetrylin cytotoxic analogues (report II). Russ J Biother 2017;2:23-9.
70. Shprakh ZS, Yartseva IV, Ignateva EV, Smirnova AP, Sushinina LP, Ustinkina SV et al. Synthesis and chemico-pharmaceutical characteristics of somatostatin analog with antitumor activity. Pharm Chem J 2014;3:159-62.
71. Mikhaevich ?I, Yavorskaya NP, Golubeva IS, Polozkova AP, Partolina SA, Oborotova NA. Studying the possibility of oral delivery of Cyphetrylin. Russ J Biother 2012;1:3-7.
72. Shprakh Z, Orlova O, Ignatieva E, Oborotova N, Bunyatyan N. Formulation and evaluation of Somatostatin analogue tablets. Int J App Pharm 2019;4:220-3.
73. Shprakh ZS, Ign?tieva ?V, Yartseva IV, Dmitricheva NA, Smirnova LI. Development and validation of cyphetrylin assay in tablets. Russ J Biother 2016;3:55-61.
74. Shprakh ZS, Borisova LM, Kiseleva MP, Smirnova ZS. Preclinical study of cyphetrylin antitumor efficiency on experimental animal tumors. Éksperimentalnaya i Klinicheskaya Farmakologiya (Experimental and Clinical Pharmacology) 2019;8:27-31.
75. Zimakova NI, Kolesnikova EY, Budko AP, Deychman ZG, Zolotarev AE, Badun GA et al. Preclinical study pharmacokinetics drug form of analog hypothalamic hormone somatostatine (AGG). Russ J Biother 2012;3:33-8.
76. Konyaeva OI, Kulbachevskaya NYu, Ermakova NP, Chaley VA, Merkulova IB, Abramova ?V et al. Pre-clinical toxicological study of analogue of hypothalamic hormone. Russ J Biother 2018;2:63-70.
Statistics
10 Views | Downloads
How to Cite
Shprakh, Z. (2020). SOMATOSTATIN ANALOGUES FOR THE TREATMENT OF NEUROENDOCRINE TUMOURS. DOSAGE FORMS AND ROUTES OF ADMINISTRATION (REVIEW). International Journal of Applied Pharmaceutics, 12(2). Retrieved from https://innovareacademics.in/journals/index.php/ijap/article/view/36558
Section
Review Article(s)